FGF21
Fibroblast growth factor 21 (FGF21) is a secreted protein and endocrine metabolic regulator with important roles in energy homeostasis, lipid metabolism, glucose handling, and adaptive stress responses.
Fibroblast growth factor 21 (FGF21) is a secreted protein and endocrine metabolic regulator with important roles in energy homeostasis, lipid metabolism, glucose handling, and adaptive stress responses. In biomedical research, it is often discussed as a hepatokine because the liver is a major source of circulating FGF21, and it has been linked to insulin sensitivity, body weight regulation, fat mass, and broader metabolic control. Its biological effects are commonly considered in the context of metabolic dysfunction–associated steatotic liver disease, obesity, and type 2 diabetes, where it is studied as both a mechanistic mediator and a therapeutic target.
FGF21 is also notable for its integration into multi-hormone and tissue-crosstalk pathways. Recent work has examined its interaction with adiponectin in a PPARα-FGF21-adiponectin axis, its relationship to growth differentiation factor 15 and metformin-related stress signaling, and its processing by fibroblast activation protein alpha (FAP), which may alter circulating substrate availability. In experimental settings, FGF21 has been combined with gene therapy, antibody-based platforms, hydrogels, and incretin-related strategies such as GLP-1 receptor agonism and GIPR antagonism, reflecting its broad therapeutic interest in metabolic disease and tissue repair.
Where the papers sit
8 papers from the last 6 months study FGF21 directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 1 observational · 5 preclinical · 1 unclassified
Themes 3 themes
-
Metabolic Liver Disease
FGF21 research is linking hepatic leptin resistance, insulin resistance and metabolic dysfunction–associated steatotic liver disease. FGF21–leptin synergy is being explored as a way to reverse obesity-related hepatic resistance and metabolic comorbidity. Fibroblast activation protein and its substrates add a liver-remodelling and disease-progression dimension. Perinatal FGF21 measurements also connect this biology with postpartum insulin resistance in gestational diabetes.
3 papers · 37.5%
-
Multi-Target Obesity Therapy
Obesity treatment is moving toward coordinated metabolic pathway engagement rather than single-target anti-adipogenic action. A GLP-1/anti-GIPR/FGF21 peptibody combines receptor-based weight and glucose effects in preclinical testing. Tirzepatide work emphasizes longer-term changes in cardiovascular risk biomarkers alongside weight loss and diabetes control. Natural anti-adipogenic compounds remain an additional route, but their role relative to engineered multi-target therapies is unresolved.
3 papers · 37.5%
-
Controlled Metabolic Gene Therapy
Regulated FGF21 expression is being developed to make gene therapy more durable and controllable. Adaptamers and ADAR-based handling of dsRNA point toward tunable control of transgene activity and treatment duration. AAV delivery is being used to produce sustained FGF21 exposure rather than repeated dosing. The main goal is systemic metabolic improvement and health-span extension through tissue-specific adaptations.
2 papers · 25%
Papers
The 8 papers from the last 6 months that study FGF21 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Metabolic Liver Disease (3)
- Perinatal Changes in Serum Fibroblast Growth Factor 21 and Their Association With Postpartum Insulin Resistance in Women With Gestational Diabetes Mellitus. The journal of obstetrics and gynaecology research · 31 Aug 2026 PMID 42669966
- FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance. Cell metabolism · 16 Jul 2026 PMID 42462724
- Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. Scandinavian journal of gastroenterology · 3 Jun 2026 PMID 42233208
Multi-Target Obesity Therapy (3)
- A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jun 2026 PMID 42372355
- Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology · 3 Jun 2026 PMID 42233927
- Bioactivity-guided isolation of anti-adipogenic diarylpentanoids from Rhamnoneuron balansae. Fitoterapia · 2 Jun 2026 PMID 42229863
Controlled Metabolic Gene Therapy (2)
- Regulatable in vivo gene expression via adaptamers. Molecular cell · 20 Oct 2026 PMID 42901161
- AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Jun 2026 PMID 42231578
By study type
Clinical trials (1)
- Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis. Journal of the American College of Cardiology · 3 Jun 2026 PMID 42233927
Observational studies and case reports (1)
- Perinatal Changes in Serum Fibroblast Growth Factor 21 and Their Association With Postpartum Insulin Resistance in Women With Gestational Diabetes Mellitus. The journal of obstetrics and gynaecology research · 31 Aug 2026 PMID 42669966
Preclinical: animal, cell and lab studies (5)
- Regulatable in vivo gene expression via adaptamers. Molecular cell · 20 Oct 2026 PMID 42901161
- FGF21 synergizes with leptin to counteract obesity-related metabolic comorbidities by reversing hepatic leptin resistance. Cell metabolism · 16 Jul 2026 PMID 42462724
- A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 29 Jun 2026 PMID 42372355
- AAV-mediated FGF21 gene therapy promotes health span extension by whole-body tissue-specific adaptations. Molecular therapy : the journal of the American Society of Gene Therapy · 3 Jun 2026 PMID 42231578
- Bioactivity-guided isolation of anti-adipogenic diarylpentanoids from Rhamnoneuron balansae. Fitoterapia · 2 Jun 2026 PMID 42229863
Unclassified: not yet indexed with MeSH (1)
- Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. Scandinavian journal of gastroenterology · 3 Jun 2026 PMID 42233208
Written from 8 PubMed abstracts, each one listed by PMID above. Published: 2026-08-11. Last written: 2026-09-02 by GPT. Drafted by language models from published abstracts; not medical advice.